ReviewPharmaceutics2025
From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Post-translational modification-regulating biomaterials for regeneration.Bioactive materials · 2026Review
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Actively targeted dendrimer-metal organic framework drug delivery nanoplatform for the treatment of neuroblastoma.RSC advances · 2026Article
- Beyond Antibiotics: The Role of Antimicrobial Polymers in Modern Therapeutics.Pharmaceutics · 2026Review
- Ethosomal nanocarriers for enhanced skin drug delivery: a comprehensive review.Molecular biology reports · 2026Review
- HSP70-targeting TKD-functionalized smart micelles for membrane-guided precision breast cancer therapy: a review.Molecular biology reports · 2026Review
- Gold Nanoparticle Complexes with PAMAM Dendrimers for In Vitro Cancer Cytotoxicity Assessment: Synthesis via Ascorbic Acid Reduction.Molecules (Basel, Switzerland) · 2026Article
- Empowering women's health with miRNA-integrated nanochemical approaches: from reproductive health to cancer care.RSC advances · 2026Review
- pH-responsive acetylated PAMAM dendrimer nanocarriers for enhanced intravesical delivery of Erdafitinib in urothelial carcinoma.Scientific reports · 2026Article
- The Current State of the Art in PAMAM and PLL Dendrimers, Boron Clusters, and Their Complexes for Biomedical Use.Biomedicines · 2026Review
- Rewriting Tumor Entry Rules: Microfluidic Polyplexes and Tumor-Penetrating Strategies-A Literature Review.Pharmaceutics · 2026Review
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
- Engineering Nanocarriers for Dopamine Stabilization and Targeted Brain Delivery: Mechanisms, Approaches and Translational Challenges.International journal of nanomedicine · 2026Review
- Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation.Frontiers in immunology · 2026Review
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Preclinical Evaluation of Nanoemulsion and Polymeric Nanocapsule Delivery Systems of 4-(Phenylselanyl)-2H-Chromen-2-One for Rheumatoid Arthritis and Comorbidities.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PAMAM dendrimers are distinguished by their capacity for functionalization, which enhances the properties of the compounds they transport, rendering them highly versatile nanoparticles with extensive applications in the biomedical domain, including drug, vaccine, and gene delivery. These dendrimers can be internalized into cells through various endocytic mechanisms, such as passive diffusion, clathrin-mediated endocytosis, and caveolae-mediated endocytosis, allowing them to traverse the cytoplasm and reach intracellular targets, such as the mitochondria or nucleus. Despite the significant challenge posed by the cytotoxicity of these nanoparticles, which is contingent upon the dendrimer size, surface charge, and generation, numerous strategies have been documented to modify the dendrimer surface using polyethylene glycol and other chemical groups to temporarily mitigate their cytotoxic effects. The potential of PAMAM dendrimers in cancer therapy and other biomedical applications is substantial, owing to their ability to enhance bioavailability, pharmacokinetics, and pharmacodynamics of active ingredients within the body. This underscores the necessity for further investigation into the optimization of internalization pathways and cytotoxicity of these nanoparticles. This review offers a comprehensive synthesis of the current literature on the diverse cellular internalization pathways of PAMAM dendrimers and their cargo molecules, emphasizing the mechanisms of entry, intracellular trafficking, and factors influencing these processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.